Fig 1.
Effect of different types and concentrations of stabilizers on the particle size and zeta potential of ROSCa nanosuspensions prepared by planetary ball mill, compared to the untreated ROSCa powder (618 μm).
Fig 2.
Effect of different types and concentrations of stabilizer on the particle size of the freeze-dried ROSCa nanoparticles prepared by planetary ball mill compared with untreated ROSCa (618 μm).
Fig 3.
Effect of different types and concentrations of polymeric solutions on the particle size of ROSCa non-milled freeze-dried suspensions compared with untreated ROSCa (618 μm).
Fig 4.
Effect of different stabilizers types and concentrations on the percent dissolved of ROSCa nanoparticles after 60 minutes compared to untreated ROSCa and non-stabilized ROSCa nanoparticles.
Table 1.
Dissolution parameters of nanoparticles formulations stabilized with different concentrations of polymer compared to non-milled freeze-dried suspensions of ROSCa and the untreated drug.
Fig 5.
(A) Particle size of ROSCa nanoparticles prepared by planetary ball milling and stabilized by 10% PVP; (B) In vitro dissolution profile of ROSCa from nanoparticle formulation stabilized by 10% PVP, compared to the untreated drug in 0.1 N HCl at 37C°.
Fig 6.
XRPD spectrum for ROSCa nanoparticles stabilized by different PVP concentrations compared to the corresponding non-milled freeze-dried suspensions and untreated ROSCa.
Fig 7.
Plasma concentration-time curve of ROSCa in rabbits after oral administration of nanoparticle formula stabilized by 10 PVP compared to the raw drug.
Table 2.
Pharmacokinetic parameters of ROSCa in rabbits after oral administration of nanoparticle formula stabilized by 10% PVP compared to the raw drug.